Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06685068
PHASE1/PHASE2

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

Sponsor: Genmab

View on ClinicalTrials.gov

Summary

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors. This trial consists of 2 parts: * Part A: Dose escalation and dose level expansion * Part B: Tumor-specific expansion with dose optimization

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

23

Start Date

2024-11-13

Completion Date

2028-06-29

Last Updated

2026-04-08

Healthy Volunteers

No

Interventions

DRUG

GEN1286

Specified dose on specified days.

Locations (4)

Massachusetts General Hospital

Boston, Massachusetts, United States

START Midwest

Grand Rapids, Michigan, United States

START San Antonio

San Antonio, Texas, United States

START Mountain Region

West Valley City, Utah, United States